Sterling Pharma Solutions

Sterling Place, Dudley, Cramlington
NE23 7QG Northumberland
UK

Contact WebSite

Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO) with more than 50 years’ experience in providing small molecule API development and manufacturing services to the pharmaceutical industry, specialising in handling challenging chemistries. Sterling manages the most complex API challenges from proof-of-concept to commercial manufacture, as well as antibody-drug conjugate (ADC) research and development bioconjugation services.

Sterling has six facilities employing more than 1,350 people: its HQ in Dudley, Northumberland, UK; a chemistry services business in Newcastle upon Tyne, UK; a site in Ringaskiddy, Co. Cork, Ireland; a dedicated bioconjugation and ADC facility in Deeside, North Wales, UK; and two sites in the US, in Cary, North Carolina and Germantown, Wisconsin.

Article

04.06.2025 • News • Pharma

Sterling Pharma Solutions and Kivu Bioscience Enter Manufacturing Pact

Sterling Pharma Solutions to produce an antibody-drug conjugate (ADC) candidate for Kivu Bioscience.

31.10.2024 • News

Sterling Pharma Solutions Expands GMP ADC Manufacturing Capacity

Sterling Pharma Solutions, a global contract development and manufacturing organization (CDMO), today announced the second phase of an expansion strategy at its Deeside, UK site to support antibody-drug conjugate (ADC) development, with a more than £10 million (€11.9 million) investment to increase GMP bioconjugation capacity.

20.03.2024 • News • Chemistry

A New Standard of Collaboration for the Pharmaceutical Industry

Headquartered in Cramlington, UK, Sterling Pharma Solutions is a contract development and manufacturing organization (CDMO) that provides a range of services to the global biopharmaceutical industry, including active pharmaceutical ingredient (API) development, scale-up and cGMP manufacturing, as well as antibody drug conjugate (ADC) R&D and clinical-scale GMP manufacturing.